Immune-Checkpoint Inhibitors in Platinum-Resistant Ovarian Cancer

Alice Indini; Olga Nigro; Csongor György Lengyel; Michele Ghidini; Angelica Petrillo; Salvatore Lopez; Francesco Raspagliesi; Dario Trapani; Shelize Khakoo; Giorgio Bogani

doi:10.3390/cancers13071663

Cancers (Apr 2021)

Immune-Checkpoint Inhibitors in Platinum-Resistant Ovarian Cancer

Alice Indini,
Olga Nigro,
Csongor György Lengyel,
Michele Ghidini,
Angelica Petrillo,
Salvatore Lopez,
Francesco Raspagliesi,
Dario Trapani,
Shelize Khakoo,
Giorgio Bogani

Affiliations

Alice Indini: Medical Oncology Unit, Fondazione IRCCS Ca’ Granda Ospedale Maggiore Policlinico, Via Francesco Sforza 35, 20122 Milan, Italy
Olga Nigro: Medical Oncology, ASST Sette Laghi, Ospedale di Circolo e Fondazione Macchi, 21100 Varese, Italy
Csongor György Lengyel: Head and Neck Surgery, National Institute of Oncology Hungary, Ráth György u. 7-9, 1122 Budapest, Hungary
Michele Ghidini: Medical Oncology Unit, Fondazione IRCCS Ca’ Granda Ospedale Maggiore Policlinico, Via Della Commenda 19, 20122 Milan, Italy
Angelica Petrillo: Medical Oncology Unit, Ospedale del Mare, Via E. Russo, and University of Study of Campania “L.Vanvitelli”, Via Pansini n.5, 80100 Naples, Italy
Salvatore Lopez: Fondazione IRCCS Istituto Nazionale dei Tumori di Milano, Via Giacomo Venezian 1, 20133 Milano, Italy
Francesco Raspagliesi: Fondazione IRCCS Istituto Nazionale dei Tumori di Milano, Via Giacomo Venezian 1, 20133 Milano, Italy
Dario Trapani: European Institute of Oncology, IRCCS, New Drug Development for Innovative Therapies, Via Ripamonti 435, 20141 Milan, Italy
Shelize Khakoo: Gynecologic Oncology Unit, Department of Medicine, The Royal Marsden NHS Foundation Trust, Downs Road, Sutton SM2 5PT, UK
Giorgio Bogani: Fondazione IRCCS Istituto Nazionale dei Tumori di Milano, Via Giacomo Venezian 1, 20133 Milano, Italy

DOI: https://doi.org/10.3390/cancers13071663
Journal volume & issue: Vol. 13, no. 7
p. 1663

Abstract

Read online

Platinum-resistant ovarian cancer (OC) has limited treatment options and is associated with a poor prognosis. There appears to be an overlap between molecular mechanisms responsible for platinum resistance and immunogenicity in OC. Immunotherapy with single agent checkpoint inhibitors has been evaluated in a few clinical trials with disappointing results. This has prompted exploration of immunotherapy combination strategies with chemotherapy, anti-angiogenics, poly (ADP-ribose) polymerase (PARP) inhibitors and other targeted agents. The role of immunotherapy in the treatment of platinum-resistant OC remains undefined. The aim of this review is to describe the immunobiology of OC and likely benefit from immunotherapy, discuss clinical trial data and biomarkers that warrant further exploration, as well as provide an overview of future drug development strategies.

Published in Cancers

ISSN: 2072-6694 (Online)
Publisher: MDPI AG
Country of publisher: Switzerland
LCC subjects: Medicine: Internal medicine: Neoplasms. Tumors. Oncology. Including cancer and carcinogens
Website: https://www.mdpi.com/journal/cancers/

About the journal

Abstract

Keywords